Studies of golimumab yield positive results

06/12/2008 | Forbes

New findings are adding to evidence that golimumab, an injectable drug, holds promise as a treatment for rheumatoid arthritis when used in combination with methotrexate. One study found that 50-mg and 100-mg doses of golimumab caused disease remission in more than 30% of patients already on methotrexate, compared with 13% of those who received placebo and methotrexate. In another trial, 38% of patients who took golimumab and methotrexate experienced a 50% reduction in symptoms, while only 29% of those who got placebo plus methotrexate experienced similar improvement.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA